Core Viewpoint - A class action has been filed against Zenas BioPharma, Inc. for allegedly misleading investors during its IPO, particularly regarding the company's financial sustainability and operational funding timeline [1][2]. Group 1: Allegations and Financial Misrepresentation - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations, claiming it could sustain operations for twenty-four months instead of the actual twelve months as disclosed in its Form 10-Q filed on November 12, 2024 [2]. - Following the revelation of these material adverse facts, Zenas BioPharma's stock price has significantly declined, closing at $8.72 on April 15, 2025, which is 48.7% lower than its IPO price [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 16, 2025, while those who choose not to participate can remain as absent class members [3]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to opt for passive involvement [3]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [4]. - The firm has a history of advocating for shareholder rights and aims to hold company executives accountable for their actions [4].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Buathongsri v. Zenas BioPharma, Inc., and it allows purchasers of Zenas BioPharma securities from the IPO to seek lead plaintiff status until June 16, 2025 [1][2]. - The lawsuit claims that Zenas BioPharma overstated its operational funding timeline, stating it could fund operations for 24 months instead of the actual 12 months disclosed later [3][4]. - As of April 15, 2025, Zenas BioPharma's stock price was $8.72, which is 48.7% lower than the IPO price of $17.00 per share [4]. Group 2: Company Background - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies [2]. - The company sold over 13 million shares during its IPO at a price of $17.00 per share [2]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading law firm in securities fraud litigation [6]. - The firm has a strong track record, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][5]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding Zenas BioPharma's financial situation, specifically overstating the duration it could fund operations with existing cash and IPO proceeds [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - Zenas BioPharma, Inc. is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, particularly regarding the funding timeline for its operations [1][3][4]. Company Overview - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies [2]. IPO Details - The company conducted its IPO on September 13, 2024, selling over 13 million shares at a price of $17.00 per share [2]. Allegations of Misleading Information - The class action lawsuit claims that the IPO's offering documents were materially false and misleading, specifically overstating the duration Zenas BioPharma could fund its operations with existing cash and expected net proceeds from the IPO [3]. - It was later revealed that Zenas BioPharma could only fund its operations for 12 months instead of the 24 months previously stated in the IPO registration statement [4]. Stock Performance - As of April 15, 2025, Zenas BioPharma's stock closed at $8.72, which is 48.7% lower than the IPO price [4]. Legal Process - Investors who purchased Zenas BioPharma securities can seek appointment as lead plaintiff in the class action lawsuit, which allows them to represent the interests of all class members [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO).Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=149531&from=4CLASS PERIOD: This lawsuit ...

NEW YORK, May 21, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Zenas BioPharma's September 2024 initial public offering ("IPO" or the "Offering"), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.So Wh ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=149376&from=3 CLASS PERIOD: This ...

Core Viewpoint - Rosen Law Firm is reminding investors of Zenas BioPharma, Inc. about a class action lawsuit related to the company's IPO, with a lead plaintiff deadline set for June 16, 2025 [1][3]. Group 1: Class Action Details - Investors who purchased Zenas BioPharma securities may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lawsuit alleges that the Registration Statement contained false or misleading statements regarding the company's financial situation, specifically overstating the duration it could fund operations with existing cash and IPO proceeds [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4].

SAN DIEGO, May 19, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the "IPO") held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Ze ...